NDA 203993 · Lundbeck Pharms LLC
Onfi
Clobazam · Oral · Benzodiazepine
OrphanLast checked: Nov 19, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 14, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
10 Phase 3, 2 recruiting
FAERS reports
24,918
19,680 serious, 1,592 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )] . The use of benzodiazepines, including ONFI, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes....
What it is approved for
From the label in effect Oct 16, 2026.
ONFI ® (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. ONFI is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older ( 1 )
Mechanism: The exact mechanism of action for clobazam, a 1,5-benzodiazepine, is not fully understood but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 14, 2012 Original approval · Type 3 - New Dosage Form OrphanReviewSummary ReviewLetter
1 products under this application
- ONFI · CLOBAZAM 2.5MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clobazam" as an intervention, any sponsor and status, largest first.
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01713946 · 366 participants · Start Apr 29, 2013 · Primary completion Oct 25, 2017
Drug: RAD001; Placebo and 2 more · For: Tuberous Sclerosis Complex-associated Refractory Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 104 sites in all
- Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut SyndromePivotal-lookingCompleted
Lundbeck LLCIndustry
NCT01160770 · 267 participants · Start Dec 2005 · Primary completion Feb 2012
Drug: Clobazam · For: Lennox-Gastaut Syndrome
- Clobazam in Patients With Lennox-Gastaut SyndromePivotal-lookingCompleted
Lundbeck LLCIndustry
NCT00518713 · 238 participants · Start Aug 2007 · Primary completion Dec 2009
Drug: Clobazam Low Dose; Clobazam Medium Dose and 2 more · For: Epilepsy; Epilepsy, Generalized; Seizures
Sites: Huntsville, Alabama; Phoenix, Arizona; Los Angeles, California · 53 sites in all
- Ketogenic Diet in Infants With Epilepsy (KIWE)Pivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT02205931 · 160 participants (planned) · Start Jan 2015 · Primary completion Jun 2018
Drug: Antiepileptic drug therapy · For: Epilepsy
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 11 sites in all
- Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)Pivotal-lookingCompleted
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT01179828 · 150 participants · Start Jul 2010 · Primary completion Apr 2015
Drug: Oxycodone 15mg; Clobazam and 2 more · For: Low Back Pain
Sites: Dep. of Anesthesiolgy and Pain Therapy, Switzerland
King's College LondonAcademic, hospital or other
NCT03678129 · 109 participants · Start Dec 7, 2018 · Primary completion Jun 27, 2025
Drug: AZD7325_10; AZD7325_20 and 2 more · For: Autism Spectrum Disorder
Sites: London, United Kingdom
- The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy ChildrenPivotal-lookingStatus unknown
Dr Cipto Mangunkusumo General HospitalAcademic, hospital or other
NCT05697614 · 100 participants (planned) · Start Mar 1, 2023 · Primary completion May 30, 2023
Drug: Valproic acid; Carbamazepin and 4 more · For: Drug Resistant Epilepsy
Sites: Jakarta Pusat, Indonesia; Jakarta, Indonesia · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure5,137
- drug ineffective3,354
- off label use2,341
- somnolence1,987
- drug interaction1,200
- fatigue1,179
- epilepsy870
- condition aggravated859
- generalised tonic-clonic seizure774
- status epilepticus738
- pneumonia719
- aggression715
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 73 |
| 2006 | 69 |
| 2007 | 84 |
| 2008 | 111 |
| 2009 | 127 |
| 2010 | 168 |
| 2011 | 140 |
| 2012 | 656 |
| 2013 | 723 |
| 2014 | 787 |
| 2015 | 997 |
| 2016 | 1,142 |
| 2017 | 1,303 |
| 2018 | 1,257 |
| 2019 | 2,057 |
| 2020 | 1,917 |
| 2021 | 2,650 |
| 2022 | 2,014 |
| 2023 | 2,184 |
| 2024 | 2,401 |
| 2025 | 2,226 |
| 2026 | 1,785 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Onfi (Clobazam)
2024 spending
$31.4M
Beneficiaries
1,143
9,712 claims
Per beneficiary
$27,500
$37.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $32,346,833 |
| 2021 | $30,009,530 |
| 2022 | $29,811,572 |
| 2023 | $31,539,755 |
| 2024 | $31,432,691 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Febrile seizures.
Mewasingh LD · BMJ Clin Evid 2014 · Systematic Review
- Prophylactic drug management for febrile seizures in children.
Offringa M, Newton R, Nevitt SJ, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A, Estes E, Aparasu R, et al. · Exp Neurol 2023 · Meta-Analysis, Research Support, N.I.H., Extramural
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R, Chiron C, Vandame D, et al. · Epilepsia Open 2024 · Systematic Review, Comparative Study
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review.
Tobiasz A, Hager M, Dwbowska J, et al. · Seizure 2025 · Systematic Review
Sponsor: Lundbeck Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.